SeqOne, a French innovator in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the Wellcome Sanger Institute. The acquisition is set to create the “largest global software pure player in the genomics space“, serving over 160 labs in more than 30 countries. “The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation,” said Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project…

L’acquisition de Congenica par la société montpelliéraine SeqOne illustre une évolution stratégique de la génomique clinique en Europe. En unissant une

Today genomics can be done quickly and cheaply, largely due to the advent of NGS, backed by technology from firms like SeqOne.

Cambridge-based Congenica is being acquired for an undisclosed sum by French company SeqOne but the new entity will retain a base at the Wellcome Sanger Institute from where it was spun out.

SeqOne, a Montpellier, France-based AI-driven genomic analysis company, acquired Congenica, a Cambridge, UK-based digital health company

SeqOne, a French innovator in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the Wellcome Sanger Institute. The acquisition is set to create the “largest global software pure player in the genomics space“, serving over 160 labs in more than 30 countries. “The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation,” said Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project…

SeqOne entend se déployer à l'international, grâce à la société compte Supernova Invest, nouvel investisseur. La PME montpelliéraine d'analyse génomique vise à aider à la prise de décision médicale,…

SeqOne a annoncé le 2 septembre la signature d’un accord définitif pour l’acquisition de la société britannique Congenica, issue du Wellcome Sanger Institute, spécialisée dans l’analyse génomique. Le montant de cette opération n’a pas été dévoilé. En acquérant Congenica, SeqOne

BayBifx and SeqOne will be at Myriad Genetics! Learn how AI-Powered NGS BioInformatics is Driving Personalized medicine! This session will focus on variant interpretation a

The acquisition positions the company as the leading global software specialist in clinical genomics.